[
  {
    "row_id": "3070MO",
    "regimen": "LY3866288",
    "drugs": [
      "LY3866288"
    ],
    "biomarkers": [
      "FGFR3"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "FORAGER-1"
  },
  {
    "row_id": "2596MO",
    "regimen": "Ipilimumab + Nivolumab + Ciforadenant",
    "drugs": [
      "Ipilimumab",
      "Nivolumab",
      "Ciforadenant",
      "nivolumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1b/2",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2592MO",
    "regimen": "Fruquintinib + Sintilimab vs Axitinib or Everolimus",
    "drugs": [
      "Fruquintinib",
      "Sintilimab",
      "Axitinib",
      "Everolimus"
    ],
    "modality": [
      "IO",
      "TKI"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2604P",
    "regimen": "Cabozantinib + KO-2806",
    "drugs": [
      "Cabozantinib",
      "KO-2806"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "FIT-001",
    "biomarkers": []
  },
  {
    "row_id": "2650P",
    "regimen": "Metastasis-directed therapies",
    "drugs": [],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "KAIROS",
    "biomarkers": []
  },
  {
    "row_id": "2635P",
    "regimen": "Immune checkpoint inhibitors",
    "drugs": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "LBA94",
    "regimen": "Lenvatinib + Everolimus vs Cabozantinib",
    "drugs": [
      "Lenvatinib",
      "Everolimus",
      "Cabozantinib"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2680eP",
    "regimen": "Immune checkpoint inhibitor combination",
    "drugs": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "FUMAHR",
    "biomarkers": []
  },
  {
    "row_id": "2639P",
    "regimen": "Immune-checkpoint inhibitors rechallenge",
    "drugs": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2638P",
    "regimen": "Anlotinib + Everolimus",
    "drugs": [
      "Anlotinib",
      "Everolimus"
    ],
    "modality": [
      "IO",
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "UC-001",
    "biomarkers": []
  },
  {
    "row_id": "2665eP",
    "regimen": "Combined immune checkpoint and TKI therapy",
    "drugs": [],
    "modality": [
      "IO",
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2609P",
    "regimen": "Tumor-Informed Whole Genome-Based (WGS) ctDNA Assay",
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2609P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2603P",
    "regimen": "lenvatinib + pembrolizumab",
    "drugs": [
      "lenvatinib",
      "pembrolizumab",
      "sunitinib"
    ],
    "population": "MIBC",
    "line": "1L",
    "phase": "Phase 3",
    "trial_id": "CLEAR",
    "biomarkers": []
  },
  {
    "row_id": "2624P",
    "regimen": "nivolumab + ipilimumab",
    "drugs": [
      "nivolumab",
      "ipilimumab",
      "sunitinib"
    ],
    "population": "MIBC",
    "phase": "Not specified",
    "trial_id": "2624P",
    "biomarkers": []
  },
  {
    "row_id": "2669eP",
    "regimen": "Spatial Transcriptomics",
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2669eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2675eP",
    "regimen": "Shared Genetic and Proteomic Architecture",
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2675eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2683eTiP",
    "regimen": "genetically-modified Tie-2 expressing monocytes",
    "population": "MIBC",
    "phase": "Phase 1",
    "trial_id": "2683eTiP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2808MO",
    "regimen": "Proton Pump Inhibitors",
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2808MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2606P",
    "regimen": "Transcriptomic predictors",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2606P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "LBA96",
    "regimen": "Pembrolizumab-based Regimens",
    "drugs": [
      "pembrolizumab"
    ],
    "population": "MIBC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "KEYMAKER-U03",
    "biomarkers": []
  },
  {
    "row_id": "2619P",
    "regimen": "Real-World Practice Patterns",
    "population": "MIBC",
    "phase": "Not specified",
    "trial_id": "2619P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2636P",
    "regimen": "Patient Perceptions of Cure",
    "population": "MIBC",
    "phase": "Not specified",
    "trial_id": "2636P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2643P",
    "regimen": "Urinary microbiome diversity",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2643P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2641P",
    "regimen": "Systemic immunosuppressive and pro-inflammatory milieu",
    "population": "MIBC",
    "phase": "Not specified",
    "trial_id": "2641P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2625P",
    "regimen": "[177Lu]Lu-PSMA-617",
    "population": "MIBC",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "RENALUT",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2631P",
    "regimen": "Unmet Needs & Disparities in Kidney Cancer",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2631P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2614P",
    "regimen": "Recurrence After Local Treatment",
    "population": "MIBC",
    "phase": "Not specified",
    "trial_id": "UroCCR Ndeg213",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2622P",
    "regimen": "systemic immunotherapy +/- resection",
    "modality": [
      "IO"
    ],
    "population": "MIBC",
    "phase": "Not specified",
    "trial_id": "UroCCR Ndeg193",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "LBA95",
    "regimen": "Neoadjuvant immunotherapy",
    "modality": [
      "IO"
    ],
    "population": "MIBC",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "NESCIO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2671eP",
    "regimen": "Sarcomatoid Dedifferentiation",
    "population": "MIBC",
    "phase": "Not specified",
    "trial_id": "ARON-1",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2651P",
    "regimen": "Cabozantinib and Sunitinib",
    "drugs": [
      "cabozantinib",
      "sunitinib"
    ],
    "population": "MIBC",
    "phase": "Not specified",
    "trial_id": "TOG",
    "biomarkers": []
  },
  {
    "row_id": "2607P",
    "regimen": "Belzutifan after PD-(L)1 inhibitor and >=2 VEGFR-TKIs",
    "drugs": [
      "Belzutifan"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": "LITESPARK-005",
    "biomarkers": []
  },
  {
    "row_id": "2629P",
    "regimen": "First Line treatment in metastatic renal cell carcinoma",
    "population": "mRCC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "Real World",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "LBA93",
    "regimen": "Adjuvant durvalumab monotherapy or combined with tremelimumab",
    "drugs": [
      "durvalumab",
      "tremelimumab"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Phase 3",
    "trial_id": "RAMPART",
    "biomarkers": []
  },
  {
    "row_id": "2642P",
    "regimen": "Immunotherapy responsiveness in clear cell renal cell carcinoma",
    "population": "ccRCC",
    "phase": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2657eP",
    "regimen": "Single cell RNA sequencing study in renal cell carcinoma",
    "population": "Other",
    "phase": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2661eP",
    "regimen": "Autophagic regulation leading to metastasis in chromophobe renal cell carcinoma",
    "population": "Other",
    "phase": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2623P",
    "regimen": "Cadonilimab Plus Lenvatinib in previously immunotherapy-treated advanced clear cell renal cell carcinoma",
    "drugs": [
      "Cadonilimab",
      "Lenvatinib"
    ],
    "population": "ccRCC",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "CLEAR-IT",
    "biomarkers": []
  },
  {
    "row_id": "2660eP",
    "regimen": "TKIs Plus PD-1 Inhibitor Therapy",
    "population": "mRCC",
    "phase": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2616P",
    "regimen": "Belzutifan versus everolimus in previously treated advanced renal cell carcinoma",
    "drugs": [
      "Belzutifan",
      "everolimus"
    ],
    "population": "RCC",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": "LITESPARK-005",
    "biomarkers": []
  },
  {
    "row_id": "2618P",
    "regimen": "Immuno-oncology-based combinations in advanced renal cell carcinoma",
    "population": "aRCC",
    "phase": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2621P",
    "regimen": "Adjuvant penpulimab in very high-risk clear cell renal cell carcinoma",
    "drugs": [
      "penpulimab"
    ],
    "population": "ccRCC",
    "line": "Adjuvant",
    "phase": "Phase 2",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2634P",
    "regimen": "PD-1 blockade plus tyrosine kinase inhibitor in advanced renal cell carcinoma",
    "drugs": [
      "PD-1 blockade",
      "tyrosine kinase inhibitor"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2630P",
    "regimen": "Single-Nucleus Atlas of Collecting Duct Carcinoma",
    "population": "Other",
    "phase": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2654eP",
    "regimen": "Multi-Omic Analysis of Collecting Duct Carcinoma",
    "population": "Other",
    "phase": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2649P",
    "regimen": "Patient experience of services in kidney cancer",
    "population": "Other",
    "phase": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2666eP",
    "regimen": "immune checkpoint inhibition",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1038",
    "regimen": "real-world data",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1053",
    "regimen": "TKIs",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2663eP",
    "regimen": "different treatment options",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "MIBC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2681eP",
    "regimen": "immunotherapy-based combinations",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ARON-1 mu"
  },
  {
    "row_id": "2662eP",
    "regimen": "combination immunotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2673eP",
    "regimen": "genomic profiling",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "MIBC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2664eP",
    "regimen": "Metastatectomy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "MIBC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2678eP",
    "regimen": "Cytoreductive Nephrectomy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "MIBC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2667eP",
    "regimen": "Dialysis Status",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2620P",
    "regimen": "Systemic Therapies",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "MIBC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2647P",
    "regimen": "Immune Checkpoint Inhibitor-based Therapies",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "MIBC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2602P",
    "regimen": "iparomlimab and tuvonralimab plus lenvatinib",
    "drugs": [
      "iparomlimab",
      "tuvonralimab",
      "lenvatinib"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "MIBC",
    "line": "Not specified",
    "phase": "Phase 1b",
    "trial_id": ""
  },
  {
    "row_id": "2648P",
    "regimen": "Sintilimab in Combination with Axitinib and Stereotactic Radiotherapy",
    "drugs": [
      "Sintilimab",
      "Axitinib"
    ],
    "biomarkers": [],
    "modality": [
      "IO",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": ""
  },
  {
    "row_id": "2626P",
    "regimen": "cabozantinib plus nivolumab",
    "drugs": [
      "cabozantinib",
      "nivolumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "MIBC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "CaboCombo"
  },
  {
    "row_id": "2628P",
    "regimen": "registry study",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2627P",
    "regimen": "HIF2-dependent Regulation",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2682eTiP",
    "regimen": "neoadjuvant zanzalintinib plus nivolumab",
    "drugs": [
      "zanzalintinib",
      "nivolumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "MIBC",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "EXPLORE-RCC"
  },
  {
    "row_id": "2676eP",
    "regimen": "Schwann Cell-Mediated Mechanisms",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1284",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1",
    "regimen": "immunotherapy",
    "phase": "Phase 3",
    "trial_id": "2601P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2",
    "regimen": "Immune-Combinations",
    "drugs": [
      "pembrolizumab"
    ],
    "population": "mRCC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2645P",
    "biomarkers": []
  },
  {
    "row_id": "3",
    "regimen": "systemic treatment",
    "population": "mRCC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2658eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "4",
    "regimen": "Cabozantinib and Nivolumab",
    "drugs": [
      "Cabozantinib",
      "Nivolumab"
    ],
    "population": "mccRCC",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "2591O",
    "biomarkers": []
  },
  {
    "row_id": "5",
    "regimen": "adjuvant pembrolizumab",
    "drugs": [
      "pembrolizumab"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "2659eP",
    "biomarkers": []
  },
  {
    "row_id": "6",
    "regimen": "Adjuvant Immune Checkpoint Inhibition",
    "phase": "Not specified",
    "trial_id": "2612P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "7",
    "regimen": "Ipilimumab",
    "drugs": [
      "Ipilimumab"
    ],
    "population": "mccRCC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2637P",
    "biomarkers": []
  },
  {
    "row_id": "8",
    "regimen": "adjuvant Pembrolizumab",
    "drugs": [
      "pembrolizumab"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "2672eP",
    "biomarkers": []
  },
  {
    "row_id": "9",
    "regimen": "nivolumab-based immunotherapy",
    "drugs": [
      "nivolumab"
    ],
    "population": "mccRCC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2674eP",
    "biomarkers": []
  },
  {
    "row_id": "10",
    "regimen": "systemic cancer treatment",
    "phase": "Phase 3",
    "trial_id": "2617P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "11",
    "regimen": "Immunotherapy",
    "phase": "Not specified",
    "trial_id": "2670eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "12",
    "regimen": "Belzutifan Plus Lenvatinib",
    "drugs": [
      "Belzutifan",
      "Lenvatinib"
    ],
    "population": "ccRCC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2615P",
    "biomarkers": []
  },
  {
    "row_id": "13",
    "regimen": "first-line treatment decisions",
    "phase": "Not specified",
    "trial_id": "2655eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "14",
    "regimen": "liquid biopsy assay",
    "phase": "Not specified",
    "trial_id": "2608P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "15",
    "regimen": "intratumoral vascular feature",
    "phase": "Not specified",
    "trial_id": "2679eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "16",
    "regimen": "[68Ga]Ga-DPI-4452 PET/CT",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2597MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "17",
    "regimen": "Nivolumab plus Ipilimumab Therapy",
    "drugs": [
      "Nivolumab",
      "Ipilimumab"
    ],
    "population": "mccRCC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2613MO",
    "biomarkers": []
  },
  {
    "row_id": "18",
    "regimen": "Novel Therapies",
    "phase": "Not specified",
    "trial_id": "ROW_1882",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "19",
    "regimen": "carboplatin dosing optimization",
    "phase": "Not specified",
    "trial_id": "2940eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2961eP",
    "regimen": "Carboplatin dose calculation based on renal function assessment",
    "drugs": [
      "carboplatin"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "1530P",
    "regimen": "NUC-7738 and PD-1 Inhibition",
    "drugs": [
      "NUC-7738"
    ],
    "biomarkers": [
      "PD-1"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2861P",
    "regimen": "Meldonium in metastatic renal cell carcinoma",
    "drugs": [
      "Meldonium"
    ],
    "modality": [],
    "population": "mRCC",
    "line": "Not specified",
    "phase": "Phase 1/2",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "2598MO",
    "regimen": "Intratumor Mycobiome Promotes Clear Cell Renal Cell Carcinoma Progression",
    "drugs": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "2600MO",
    "regimen": "Ipilimumab/Nivolumab versus standard of care",
    "drugs": [
      "Ipilimumab",
      "Nivolumab",
      "nivolumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "SUNNIFORECAST",
    "biomarkers": [
      "PD-L1"
    ]
  },
  {
    "row_id": "2599MO",
    "regimen": "Soluble MAdCAM-1 predicts outcomes in metastatic renal cell carcinoma",
    "drugs": [],
    "modality": [],
    "population": "mRCC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "2595MO",
    "regimen": "Ipilimumab plus Nivolumab vs standard of care",
    "drugs": [
      "Ipilimumab",
      "Nivolumab",
      "nivolumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "SUNNIFORECAST",
    "biomarkers": []
  },
  {
    "row_id": "1547P",
    "regimen": "Acquired Resistance to Checkpoint Inhibitors",
    "drugs": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "2610MO",
    "regimen": "Genomic Analysis of Papillary Renal Cell Carcinoma",
    "drugs": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "2963eP",
    "regimen": "Nivolumab",
    "drugs": [
      "Nivolumab",
      "nivolumab"
    ],
    "biomarkers": [
      "GDF-15"
    ],
    "modality": [
      "IO"
    ],
    "population": "mRCC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2593MO",
    "regimen": "Immunotherapy response in metastatic renal cell carcinoma",
    "drugs": [],
    "biomarkers": [
      "LAG3"
    ],
    "modality": [
      "IO"
    ],
    "population": "mRCC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2594MO",
    "regimen": "Circulating kidney injury molecule-1 levels with clinical outcomes",
    "drugs": [],
    "biomarkers": [
      "KIM-1"
    ],
    "modality": [],
    "population": "aRCC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "COSMIC-313"
  },
  {
    "row_id": "64eP",
    "regimen": "Patient-Derived Organoids in Renal Cell Carcinoma",
    "drugs": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "277eP",
    "regimen": "First-Line Immune Checkpoint Blockade",
    "drugs": [],
    "modality": [
      "IO"
    ],
    "population": "mRCC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "44eP",
    "regimen": "Biologically Targeted Dual Adaptive and Innate Nano-Immunotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "254eP",
    "regimen": "Urinary Sediment SNORD4A as a Novel Diagnostic Biomarker",
    "drugs": [],
    "biomarkers": [
      "SNORD4A"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "68eP",
    "regimen": "Secretory GPX3 promotes lung metastasis",
    "drugs": [],
    "biomarkers": [
      "GPX3"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "228eP",
    "regimen": "Impact on immunotherapy outcomes",
    "drugs": [],
    "biomarkers": [
      "ABCA1",
      "ABCG1"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "CHOMET"
  },
  {
    "row_id": "2605MO",
    "regimen": "Final efficacy data and biomarker analysis",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2632P",
    "regimen": "Second-line patterns and outcomes",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2652eP",
    "regimen": "Succinate-dehydrogenase B protein expression and prognosis",
    "drugs": [],
    "biomarkers": [
      "succinate-dehydrogenase B"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2601P",
    "regimen": "immunotherapy",
    "drugs": [
      "immunotherapy"
    ],
    "modality": [
      "IO"
    ],
    "population": "mUC",
    "line": "1L",
    "phase": "Phase 3",
    "trial_id": "2601P",
    "biomarkers": []
  },
  {
    "row_id": "2645P",
    "regimen": "Immune-Combinations",
    "drugs": [
      "Immune-Combinations"
    ],
    "modality": [
      "IO"
    ],
    "population": "mUC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2645P",
    "biomarkers": []
  },
  {
    "row_id": "2658eP",
    "regimen": "systemic treatment",
    "drugs": [
      "systemic treatment"
    ],
    "modality": [
      "IO"
    ],
    "population": "mUC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2658eP",
    "biomarkers": []
  },
  {
    "row_id": "2591O",
    "regimen": "Cabozantinib and Nivolumab",
    "drugs": [
      "Cabozantinib",
      "Nivolumab",
      "nivolumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "mUC",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "2591O",
    "biomarkers": []
  },
  {
    "row_id": "2659eP",
    "regimen": "adjuvant pembrolizumab",
    "drugs": [
      "pembrolizumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "mUC",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "2659eP",
    "biomarkers": []
  },
  {
    "row_id": "2612P",
    "regimen": "Adjuvant Immune Checkpoint Inhibition",
    "drugs": [
      "Immune Checkpoint Inhibition"
    ],
    "modality": [
      "IO"
    ],
    "population": "mUC",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "2612P",
    "biomarkers": []
  },
  {
    "row_id": "ROW_1431",
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2637P",
    "regimen": "First Line Ipilimumab",
    "drugs": [
      "Ipilimumab",
      "nivolumab"
    ],
    "population": "mUC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2672eP",
    "regimen": "Adjuvant Pembrolizumab",
    "drugs": [
      "Pembrolizumab",
      "pembrolizumab"
    ],
    "population": "MIBC",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "ARON-1",
    "biomarkers": []
  },
  {
    "row_id": "2674eP",
    "regimen": "Nivolumab-based immunotherapy",
    "drugs": [
      "Nivolumab",
      "nivolumab"
    ],
    "population": "MIBC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2617P",
    "regimen": "Coaching on side effects of systemic cancer treatment",
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 3",
    "trial_id": "PREPARE",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2670eP",
    "biomarkers": [
      "SPP1"
    ],
    "population": "MIBC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "drugs": []
  },
  {
    "row_id": "2615P",
    "regimen": "Belzutifan Plus Lenvatinib",
    "drugs": [
      "Belzutifan",
      "Lenvatinib"
    ],
    "population": "mUC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "LITESPARK-010",
    "biomarkers": []
  },
  {
    "row_id": "2655eP",
    "population": "MIBC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "VOCALIZE",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2608P",
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2679eP",
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2597MO",
    "modality": [
      "PET/CT"
    ],
    "population": "Other",
    "trial_id": "2597MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2613MO",
    "regimen": "Nivolumab plus Ipilimumab Therapy",
    "drugs": [
      "Nivolumab",
      "Ipilimumab",
      "nivolumab"
    ],
    "biomarkers": [
      "PD-L1"
    ],
    "population": "mUC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "COSMIC 313"
  },
  {
    "row_id": "ROW_1882",
    "regimen": "Novel Therapies",
    "population": "Other",
    "trial_id": "ROW_1882",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2940eP",
    "regimen": "Carboplatin Dosing Optimization",
    "population": "Other",
    "trial_id": "2940eP",
    "drugs": [
      "carboplatin"
    ],
    "biomarkers": []
  },
  {
    "row_id": "ROW_2203",
    "trial_id": "ROW_2203",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_2254",
    "trial_id": "ROW_2254",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_2255",
    "trial_id": "ROW_2255",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "CN74",
    "regimen": "Clinical Nurse Specialist and Specialist Pharmacist Clinics",
    "population": "Other",
    "trial_id": "CN74",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_2874",
    "trial_id": "ROW_2874",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_3093",
    "trial_id": "ROW_3093",
    "drugs": [],
    "biomarkers": []
  }
]